Latest Breaking News On - Cytovant sciences hk ltd - Page 1 : comparemela.com

Identification of ten novel tumor-specific antigens immunogenic for T cells Planegg/Martinsried and Montréal - 10 April 2021. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today presents the screening and identification of novel immunogenic tumor-specific antigens (TSAs) derived from non-coding regions of the human genome at the American Association for Cancer Research Virtual Annual Meeting (AACR) 2021. The poster can be found on Medigene s website: https://www.medigene.com/technologies/abstracts Significant efforts are being dedicated worldwide to identifying novel TSAs as targets for cancer immunotherapy. In this respect, not only known proteins but also non-coding genetic regions of cells are studied as sources of peptides that can be presented by HLA molecules at the surface of tumor cells and be recognized by T cell receptors (TCRs). Such TSAs can provide new targets that all

United statesGary waandersSteven kleinDolores schendelAnna niedlPlanegg martinsriedMary ann changDesbois mackenzieCentre of excellenceCytovant sciences hk ltdInstitute for researchCommunications advisorBusiness developmentPrime standardAmerican associationCancer research virtual annual meeting